Manji H K, Hsiao J K, Risby E D, Oliver J, Rudorfer M V, Potter W Z
Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, Md 20892.
Arch Gen Psychiatry. 1991 Jun;48(6):505-12. doi: 10.1001/archpsyc.1991.01810300017003.
The effects of 2 weeks of lithium carbonate administration at therapeutic plasma levels were examined in 11 normal volunteers. Serotoninergic function before and after lithium administration was assessed using low-dose intravenous clomipramine hydrochloride challenge, while urinary and plasma metabolites of norepinephrine (NE) were used to assess noradrenergic systems. Long-term lithium administration in normal subjects did not significantly or consistently enhance serotonin-mediated neuroendocrine responses but did increase measures related to neuronal release of NE. No statistically significant effects of lithium on prolactin, corticotropin, or cortisol responses to serotoninergic challenge could be detected. The probability of a type II error was assessed, and a doubling of prolactin level was unlikely to have been missed, although more modest increases (less than 75%) could have been overlooked. After 2 weeks of lithium administration, there were significant increases in 24-hour urinary excretion of NE, normetanephrine, and fractional NE release, compatible with increased neuronal release of NE and a lithium-induced subsensitivity in alpha 2-adrenergic receptor function. These changes were not statistically significant after 1 week of administration, suggesting that increased NE release is characteristic of long- rather than short-term lithium administration. Since previous reports have demonstrated enhanced prolactin responses after short- but not long-term lithium use, the present study points to temporal specificity in lithium's effects on both serotoninergic and noradrenergic function. Lithium's effects on NE release were consistent but small (a 16% increase), while its effects on serotoninergic responses were larger (a 50% increase in prolactin responses) but quite inconsistent, suggesting that neither of these systems is the primary site of action of lithium.
在11名正常志愿者中研究了以治疗性血浆水平给予碳酸锂2周的效果。使用低剂量静脉注射盐酸氯米帕明激发试验评估锂给药前后的血清素能功能,同时使用去甲肾上腺素(NE)的尿液和血浆代谢产物评估去甲肾上腺素能系统。正常受试者长期服用锂并未显著或持续增强血清素介导的神经内分泌反应,但确实增加了与NE神经元释放相关的指标。未检测到锂对血清素能激发试验中催乳素、促肾上腺皮质激素或皮质醇反应有统计学显著影响。评估了II型错误的概率,催乳素水平翻倍不太可能被遗漏,尽管更适度的增加(小于75%)可能被忽略。服用锂2周后,NE、去甲变肾上腺素的24小时尿排泄量和NE的分数释放显著增加,这与NE神经元释放增加以及锂诱导的α2-肾上腺素能受体功能亚敏感性一致。给药1周后这些变化无统计学显著性,表明NE释放增加是长期而非短期锂给药的特征。由于先前的报告表明短期而非长期使用锂后催乳素反应增强,本研究指出锂对血清素能和去甲肾上腺素能功能的影响具有时间特异性。锂对NE释放的影响是一致的但较小(增加16%),而其对血清素能反应的影响较大(催乳素反应增加50%)但非常不一致,这表明这两个系统都不是锂的主要作用位点。